...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America. >Selective tumor antigen vaccine delivery to human CD169(+) antigen-presenting cells using ganglioside-liposomes
【24h】

Selective tumor antigen vaccine delivery to human CD169(+) antigen-presenting cells using ganglioside-liposomes

机译：Selective tumor antigen vaccine delivery to human CD169(+) antigen-presenting cells using ganglioside-liposomes

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Priming of CD8(+) T cells by dendritic cells (DCs) is crucial for the generation of effective antitumor immune responses. Here, we describe a liposomal vaccine carrier that delivers tumor antigens to human CD169/Siglec-1(+) antigen-presenting cells using gangliosides as targeting ligands. Ganglioside-liposomes specifically bound to CD169 and were internalized by in vitro-generated monocyte-derived DCs (moDCs) and macrophages and by ex vivo-isolated splenic macrophages in a CD169-dependent manner. In blood, high-dimensional reduction analysis revealed that ganglioside-liposomes specifically targeted CD14(+) CD169(+) monocytes and Axl(+) CD169(+) DCs. Liposomal codelivery of tumor antigen and Toll-like receptor ligand to CD169(+) moDCs and Axl(+) CD169(+) DCs led to cytokine production and robust cross-presentation and activation of tumor antigen-specific CD8(+) T cells. Finally, Axl(+) CD169(+) DCs were present in cancer patients and efficiently captured ganglioside-liposomes. Our findings demonstrate a nanovaccine platform targeting CD169(+) DCs to drive antitumor T cell responses.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号